Ann Eapen, MD, from UC-Irvine Department of Hematology and Oncology is presenting the CLARITY Trial (Bloodwise TAP Study) which looks at the high rates of overall response, complete remission, and MRD eradication after 6 months of combination therapy at the MOASCs “Spotlight On: Hematology” in Huntington Beach.
Initial Results of Ibrutinib Plus Venetoclax in Relapsed Refractory CLL
